MktsMarkets

Heron Therapeutics, Inc.
NASDAQ: HRTXKey statistics
HRTX News
Stories mentioning HRTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | 10,638 | 11,119 | 11,914 | 9,857 | 8,457 | 10,228 | 9,458 | 10,518 |
| Gross Profit | 24,073 | 29,469 | 26,299 | 27,343 | 30,446 | 30,553 | 23,352 | 25,506 |
| Operating Expenses | ||||||||
| Research & Development | 2,385 | 3,746 | 3,470 | 2,934 | 2,279 | 3,178 | 4,465 | 4,432 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (4,765) | 38.00 | (4,093) | (1,637) | 3,154 | 4,173 | (4,458) | (6,445) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (3,346) | 4,665 | (2,063) | (744.00) | (519.00) | 1,972 | (390.00) | (2,790) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (8,111) | (2,954) | (17,495) | (2,381) | 2,635 | 3,663 | (4,848) | (9,235) |
| Earnings Per Share (Basic) | (0.04) | (0.02) | (0.10) | (0.02) | 0.02 | 0.02 | (0.03) | (0.06) |
| Earnings Per Share (Diluted) | (0.04) | (0.02) | (0.10) | (0.02) | 0.01 | 0.02 | (0.03) | (0.06) |
| Weighted Average Shares Outstanding (Basic) | 189,646 | 166,707 | 170,348 | 154,020 | 153,490 | 152,449 | 152,830 | 152,305 |
| Weighted Average Shares Outstanding (Diluted) | 189,646 | 166,707 | 170,348 | 154,020 | 196,921 | 152,449 | 152,830 | 152,305 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About HRTX
Heron Therapeutics, Inc. (NASDAQ: HRTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol HRTX. It last traded at $0.2800 (Nov 5, 2026, 9:30 AM ET), down 8.2% on the day. That gives Heron Therapeutics a market capitalisation of $54.1M.
Over the past 52 weeks HRTX has traded between $0.2600 and $1.58.
For the quarter ended Mar 31, 2026 it reported a net loss of $8.1M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$8.1M |
| Dec 31, 2025 | — | -$3.0M |
| Sep 30, 2025 | — | -$17.5M |
| Jun 30, 2025 | — | -$2.4M |
From Heron Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…